Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30800577 | 1.00 | ESR2 (0.59) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL29390905 | 1.00 | ESR2 (0.59) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL27087855 | 1.00 | ESR2 (0.59) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL30184058 | 0.87 | ESR2 (0.60) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL28380071 | 0.87 | ESR2 (0.60) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL18875033 | 0.87 | ESR2 (0.57) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL18875037 | 0.87 | ESR2 (0.57) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL30875704 | 0.87 | ESR2 (0.60) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL31335703 | 0.86 | ESR2 (0.56) | ESR2NR1H2MAPTLMNAALDH1A1 | |
| SCHEMBL29557441 | 0.86 | ESR2 (0.56) | ESR2NR1H2MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919904-B2 | Sulfonylamide compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-11384083-B2 | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3923949-A1 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | Incyte Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20200399273-A1 | SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-20200392139-A1 | PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-20200316064-A1 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | INCYTE CORPORATION | 2020-10-08 | — | — | US | disclosed |
| WO-2020168178-A1 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | INCYTE CORPORATION (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168197-A1 | PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392139-A1 | PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | ESR2 2117/4885NR1H2 4331/4885MAPT 3406/4885 |
| US-20200316064-A1 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | CDK2, CDK2AP2, CDKL2 | ESR2 968/4885NR1H2 3641/4885MAPT 3453/4885 |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | ESR2 3298/4885NR1H2 3160/4885MAPT 4831/4885 |
| US-11919904-B2 | Sulfonylamide compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | ESR2 570/4885NR1H2 2555/4885MAPT 4368/4885 |
| US-11384083-B2 | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors | CDK2, CCNI, CCNK | ESR2 1104/4885NR1H2 1851/4885MAPT 3937/4885 |
| US-20200399273-A1 | SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | ESR2 570/4885NR1H2 2555/4885MAPT 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.